



## **COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position**

**February 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.**

“In her ten years at InDex, Pernilla has successfully built up a highly qualified and effective development organisation, which ensures that the work to take the drug candidate cobitolimod through phase III will continue according to plan. Phase III is the final stage of development before application for market approval. I want to direct a warm thanks to Pernilla for an excellent collaboration and wish her all the best in her next assignment,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

“It is with mixed emotions that I have decided to accept the offer of a CEO position. I am very proud to have contributed to the development of InDex and I strongly believe in the potential of the company and cobitolimod. The phase III study CONCLUDE is up and running and I am convinced the team will complete it in the best possible way,” said Pernilla Sandwall.

### **For more information:**

Peter Zerhouni, CEO

Phone: +46 8 122 038 50

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

### **Publication**

The information was submitted for publication through the agency of the contact person set out above at 21:00 CET on February 13, 2022.

### **InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with email address [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com).